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Background: There are currently no treatments that stop or slow the progression of 62 
Parkinson’s disease (PD). Case-control genome-wide association studies have 63 
identified variants associated with disease risk, but not progression. 64 
Objective: To identify genetic variants associated with PD progression. 65 
Methods: We analysed three large, longitudinal cohorts: Tracking Parkinson’s, Oxford 66 
Discovery, and the Parkinson’s Progression Markers Initiative. We included clinical 67 
data for 3,364 patients with 12,144 observations (mean follow-up 4.2 years). We used 68 
a new method in PD, following a similar approach in Huntington’s disease, where we 69 
combined multiple assessments using a principal components analysis to derive 70 
scores for composite, motor, and cognitive progression. These scores were analysed 71 
in linear regressions in genome-wide association studies. We also performed a 72 
targeted analysis of the 90 PD risk loci from the latest case-control meta-analysis. 73 
Results: There was no overlap between variants associated with PD risk, from case-74 
control studies, and PD age at onset versus PD progression. The APOE 4 tagging 75 
variant, rs429358, was significantly associated with composite and cognitive 76 
progression in PD. Conditional analysis revealed several independent signals in the 77 
APOE locus for cognitive progression. No single variants were associated with motor 78 
progression. However in gene-based analysis, ATP8B2, a phospholipid transporter 79 
related to vesicle formation, was nominally associated with motor progression 80 
(p=5.3x10-6). 81 
Conclusions: We provide early evidence that this new method in PD improves 82 
measurement of symptom progression. We show that the APOE 4 allele drives 83 
progressive cognitive impairment in PD. Replication of this method and results in 84 
independent cohorts is needed. 85 





Progression in Parkinson’s disease (PD) is heterogeneous, with some patients 88 
progressing rapidly while others remain relatively stable over time1. There is a clear 89 
need to identify genetic variants that affect symptom progression in PD. These genes 90 
and pathways could be targeted to develop therapies to stop or slow progression of 91 
PD. Genetic factors could also help to stratify patients and predict progression more 92 
accurately in clinical trials. 93 
Genome-wide association studies (GWASs) in PD have identified 90 independent loci 94 
associated with disease risk2. However, the majority of PD GWASs have compared 95 
cases to healthy controls to identify variants linked to disease status. In order to identify 96 
variants that are associated with disease progression, it is necessary to compare 97 
phenotypes within patients. 98 
Progression of clinical signs in PD can be measured in different ways3 and there is no 99 
gold standard measure of progression, although the MDS-UPDRS Part III and Part II 100 
are commonly used in clinical trials. Individual scales, including the MDS-UPDRS, are 101 
affected by measurement error particularly for change over time4, including rater 102 
subjectivity and practice effects in cognitive assessments. Therefore, combining 103 
multiple measures may improve the accuracy of measuring progression5,6, as shown 104 
in the Huntington’s disease (HD) progression GWAS7. In this study, we analysed data 105 
from three large, prospective, longitudinal studies: Tracking Parkinson’s, Oxford 106 
Parkinson’s Disease Centre Discovery, and Parkinson’s Progression Markers Initiative 107 
(PPMI). We combined multiple measures of motor and cognitive progression using 108 
Principal Components Analysis (PCA) to create progression scores. These scores 109 
were analysed in GWASs to identify variants associated with composite (cross-110 
domain), motor, and cognitive progression in PD.  111 
METHODS 112 
Standard quality control procedures were performed in PLINK v1.9. The cohorts were 113 
genotyped, filtered and imputed separately, but following the same quality control 114 
steps. Only variants with minor allele frequency >1% were included. The three 115 




principal components were generated and outliers removed (see Supplementary 117 
Methods and Supplementary Figures 1-2). 118 
Clinical outcome measures 119 
Individual-level data from the cohorts was merged. In order to increase power and the 120 
accuracy of the final progression scores, we performed all transformations and created 121 
progression scores from the merged dataset as follows (Figure 1). 122 
Motor progression was assessed using the MDS-UPDRS Part III (clinician-assessed 123 
movement examination), MDS-UPDRS Part II (patient-reported experiences of daily 124 
living), and Hoehn and Yahr stage (clinician-assessed rating of impairment and 125 
disability)8,9. In PPMI, we used motor assessments conducted in the ‘off’ medication 126 
state.  127 
Cognitive progression was assessed using the Montreal Cognitive Assessment 128 
(MoCA), semantic fluency, and item 1.1 of the MDS-UPDRS (cognitive impairment 129 
based on patient and/or caregiver report). 130 
Raw scores were transformed into percentages and standardised to the population 131 
baseline mean and standard deviation within each cohort (Supplementary Methods).  132 
Analysis 133 
Progression scores 134 
We derived severity scores from mixed effects regression models using follow-up data 135 
up to 72 months. Each variable was regressed on age at onset, sex, cohort, and their 136 
interactions with time from disease onset. PD onset was based on participants’ self-137 
reported symptom onset. For the cognitive measures, we included the number of years 138 
of education before higher education, and whether higher education was undertaken. 139 
We included terms for subject random effects to account for individual heterogeneity 140 
in the intercept (baseline values) and slope (rate of progression).  141 
We used the random effect slope values as the measure of ‘residual’ progression not 142 
predicted by age at onset, cohort, gender, and education, for each individual. We 143 




The final progression scores from the PCAs relate to the variability explained, and 145 
therefore the direction cannot be strictly interpreted. Patients who were missing clinical 146 
data (e.g. MDS-UPDRSIII total) at all visits were not included in the PCA and 147 
subsequent GWAS analysis.  148 
Removal of non-PD cases 149 
Any patients that were diagnosed with a different condition during follow-up were 150 
removed from analyses. We also conducted sensitivity analyses to remove any cases 151 
which may have non-PD conditions but an alternative diagnosis had not yet been 152 
confirmed. Firstly, we removed patients in Tracking Parkinson’s and Oxford Discovery 153 
who had a clinician-rated diagnostic certainty of PD <90%10,11. Secondly, we removed 154 
the fastest and slowest progressors in the top and bottom 5% of the distribution, to 155 
address the possibility of confounding by misdiagnosis with more benign (e.g. 156 
essential tremor) or more malignant (e.g. multiple system atrophy) conditions.  157 
GWAS 158 
For each GWAS, we included the following covariates: cohort (to adjust for differences 159 
in genotyping data and measurement error) and the first 5 genetic principal 160 
components from the merged genotype data (to adjust for population substructure). 161 
GWASs were conducted in rvtests12 using the single variant Wald test. Genome-wide 162 
Complex Trait Analysis conditional and joint analysis (GCTA-COJO) was used to 163 
identify independent signals13,14. Individuals carrying rare variants in GBA, LRRK2 or 164 
other PD genes were not excluded from the GWASs. We also performed sex-stratified 165 
analysis to identify if there are different genetic associations in men and women.  166 
Genetic risk scores were calculated from the 90 loci from the PD case-control GWAS2 167 
and we analysed the association with each progression score using linear regression. 168 
GBA 169 
We analysed GBA rare variant carriers compared to non-carriers in a subset of 170 
patients, using Sanger sequencing data from Tracking Parkinson’s and whole genome 171 
sequencing data from PPMI. In PPMI, only the following GBA variants were covered: 172 




GBA variant, including Gaucher’s Disease variants and variants associated with PD 174 
but excluding novel variants, using previous studies15,16. We analysed GBA status in 175 
relation to the progression scores using linear regressions, adjusting for cohort and 176 
the first 5 genetic principal components. 177 
Levodopa-equivalent Daily Dose (LEDD)-adjusted sensitivity analyses 178 
Medication may affect MDS-UPDRSIII scores, in particular in Tracking Parkinson’s 179 
and Oxford Discovery where patients were assessed in the ‘on’ state. To address this, 180 
we performed a sensitivity analysis adjusting for LEDD, as described in a previous 181 
study, where we estimated the effect of levodopa on the MDS-UPDRSIII11 182 
(Supplementary Methods). Merely adjusting for treatment as a covariate is not 183 
adequate, as therapy is not a simple confounder but a direct outcome of the underlying 184 
symptom – individuals who have more severe symptoms are more likely to be 185 
treated17, and most likely with higher doses.  186 
 187 
RESULTS 188 
We included clinical data for 3,364 PD patients with 12,144 observations (Table 1). 189 
The mean follow-up time was 4.2 years (SD=1.5 years), and mean disease duration 190 
at study entry 2.9 years (SD=2.6 years). 79.7% of patients had completed the 72-191 
month follow-up visit.  192 
Within the motor progression PCA, the first principal component explained 61.0% of 193 
the total variance. Within the cognitive domain PCA, the first principal component 194 
explained 59.8% of the total variance (Supplementary Figures 3-6). 195 
We found that the first principal components for motor and cognitive progression were 196 
moderately correlated (r=-0.35, p < 2.2 x 10-16; Supplementary Table 1). We therefore 197 
conducted a PCA combining all motor and cognitive measures, to create a composite 198 
progression score. The first principal component from this cross-domain PCA 199 
accounted for 41.0% of the joint variance (Supplementary Figures 7-8). 200 




composite principal components are correlated. None of the principal components 202 
were associated with cohort (all p-values >0.9).  203 
GWAS of composite progression  204 
After quality control, imputation, and merging, 5,918,868 variants were available for 205 
analysis. 2,755 PD patients had composite progression scores and passed genetic 206 
quality control. All GWAS lambdas were <1.05. One variant rs429358 in Chromosome 207 
19 passed genome-wide significance (p=1.2x10-8, Figure 2, Supplementary Table 7, 208 
Supplementary Figures 9-10). This variant tags the APOE 4 allele. In the gene-based 209 
test, APOE, TOMM40 and APOC1 reached significance (p<2.8x10-6, correcting for the 210 
number of mapped protein coding genes). When we performed conditional analysis 211 
on the top SNP rs429358, there were no other SNPs that passed significance in this 212 
region (Supplementary Figure 11). The Reactome pathway cytosolic sulfonation of 213 
small molecules pathway was significantly enriched (p=6.9x10-6). 214 
GWAS of motor progression  215 
2,848 PD patients had motor progression scores and genotype data. No variants 216 
passed genome-wide significance (Figure 3, Supplementary Table 8). However, in the 217 
gene-based test, ATP8B2 in Chromosome 1 was associated with motor progression 218 
(p=5.3x10-6, Supplementary Figures 12-13), although this did not reach significance 219 
correcting for the number of mapped genes (p=2.81x10-6).  220 
We conducted follow-up GWASs in each cohort separately (Supplementary Table 9) 221 
and each motor scale separately (without combining in PCA) to confirm that the results 222 
were not driven by a single cohort, or a single scale. These results show that 223 
associations are strengthened with the PCA approach (Supplementary Table 10). 224 
Our top variant in Chromosome 1, rs35950207, was associated with motor 225 
progression, p=5.0x10-6.  We examined the associations for this SNP in the previous 226 
progression GWAS18 (https://pdgenetics.shinyapps.io/pdprogmetagwasbrowser/); 227 
rs35950207 was not significantly associated with binomial analysis of Hoehn and Yahr 228 




rs35950207 is a variant 2kb upstream of AQP10. It is an expression quantitative trait 230 
loci (eQTL) for AQP10 in whole blood (GTEx p=1.7x10-6, eQTLGen p=3.62x10-139) and 231 
other tissues (subcutaneous adispose, skin, esophagus, testis, and heart). It is also 232 
an eQTL for ATP8B2 in blood (GTEx p=1.5x10-5, eQTLGen p=7.84x10-42) and in the 233 
cerebellum (GTEx p=7.8x10-5). GBA is also located in Chromosome 1 and GBA 234 
variants are associated with both PD risk and progression19. However, rs35950207 is 235 
not in linkage disequilibrium with any of the main GBA variants that are implicated in 236 
PD (p.E326K, p.N370S, p.L444P, p.T369M).  237 
rs17367669 in Chromosome 5 was the top SNP in the variant-based analysis, but 238 
there were no genes in this region that approached significance in the gene-based 239 
analysis. This variant is closest to LOC100505841, Zinc Finger Protein 474-Like gene. 240 
No significant eQTLs were identified for this variant.  241 
GWAS of cognitive progression  242 
2,788 patients had cognitive progression scores and genotype data. The top variant 243 
was rs429358, which tags the APOE ε4 allele (p=2.53x10-13 , Figure 4, Supplementary 244 
Table 11, Supplementary Figure 14-15). Supplementary Figure 16 shows that ε4 245 
carriers had more severe cognitive progression. APOE, was also significantly 246 
associated with cognitive progression in the gene-based analysis, in addition to 247 
APOC1 and TOMM40. Follow-up analyses showed that the effects for the top 5 248 
independent SNPs were consistent in each cohort and each scale (Supplementary 249 
Tables 12-13). 250 
When we performed conditional analysis on the top SNP rs429358, a group of SNPs 251 
still passed genome-wide significance, indicating independent signals (Supplementary 252 
Figure 17). The top SNP was rs6857 (beta=-0.33, p=4.4 x 10-11). This is a 3’ UTR 253 
Variant in NECTIN2. We also conditioned on the other APOE SNP rs7412 in addition 254 
to rs429358 (if both rs429358 and rs7412 harbour the C alleles then this codes the 4 255 
allele). This did not change the results. 256 
When conditioning on both rs429358 and rs6857, there were still several SNPs that 257 




We found similar frequencies of APOE genotypes to previous studies20 259 
(Supplementary Table 14). 260 
LEDD-adjusted analyses 261 
When we performed GWASs of composite progression and motor progression after 262 
adjusting for LEDD, we did not find substantial differences. No SNPs passed genome-263 
wide significance. The top SNP for composite progression was still rs429358, and this 264 
was in the same direction and similar effect size as in the main analysis (=0.33, 265 
p=8.8x10-8). For motor progression, the top SNP was also the same as in the main 266 
analysis, and ATP8B2 and AQP10 still the top genes in the MAGMA gene analysis, 267 
though not genome-wide significant. 268 
Sex-stratified analyses 269 
The APOE locus passed genome-wide significance only in men for composite 270 
progression and cognitive progression (p<5x10-8). Other than this locus, there were 271 
no SNPs that passed significance. These analyses are underpowered and sex 272 
differences need to be investigated in more detail. 273 
Targeted assessment of PD risk loci 274 
Of the 90 risk variants from the PD case-control GWAS2, 73 were present in our final 275 
dataset, including the SNCA and TMEM175/GAK variants associated with PD age at 276 
onset21. No variants passed analysis-wide significance (p=0.05/73). Variants with at 277 
least one association p<0.05 are shown in Supplementary Figure 18. 278 
We found that only a small number of risk variants were associated with progression 279 
with p-values <0.05. rs35749011 was associated with both composite progression 280 
(beta=0.40, p=0.003) and cognitive progression (beta=-0.37, p=0.002), but not motor 281 
progression (beta=0.20, p=0.09). This variant is in linkage disequilibrium with the GBA 282 
p.E326K variant (also known as p.E365K), D’=0.90, R2=0.78. 283 
We also extracted results for other candidate variants that have been implicated in PD 284 
progression (Supplementary Figure 19). We did not find that the top variant rs382940 285 
in SLC44A1 that was associated in progression to H&Y stage 3 from the Iwaki GWAS18 286 




Overall, we did not find any overlap between the variants associated with PD risk, age 288 
at onset, and progression. Our LDSC results also suggested very little overlap 289 
between the each of the progression GWASs and PD case-control GWAS (all p-values 290 
>0.5).  291 
PD Genetic risk score 292 
73 PD risk SNPs were present in our genotype data, and 2 proxies were identified for 293 
missing variants (Supplementary Table 15). The risk score was nominally associated 294 
with cognitive progression (beta=-0.098, p=0.04) but not composite (beta=0.09, 295 
p=0.12), or motor progression (beta=0.02, p=0.69).  296 
GBA 297 
GBA data was available for 2,020 patients from Tracking Parkinson’s and PPMI. 194 298 
(9.6%) carried a pathogenic variant in GBA (Supplementary Table 16). GBA status 299 
was significantly associated with composite progression (beta=0.40, p=0.001) and 300 
cognitive progression (beta=-0.35, p=0.0008), but not motor progression (beta=0.18, 301 
p=0.10). 302 
Removal of potential non-PD cases 303 
Removing patients with <90% diagnostic certainty did not substantially affect our 304 
results; the top signals had slightly weaker associations in these sensitivity analyses. 305 
When we removed the extreme 5% of progressors, the top results from the main 306 
GWASs had larger p-values, although the direction of effects were the same 307 
(Supplementary Tables 17-18). 308 
 309 
DISCUSSION 310 
We used a new method of analysing clinical progression in PD, by combining multiple 311 
assessments in a data-driven PCA to derive scores of composite, motor, and cognitive 312 
progression in large clinical cohorts. 313 
Our study contributes to evidence that improving the phenotypic measure can increase 314 




when using the combined motor and cognitive progression scores compared to using 316 
the scales separately. The HD progression GWAS also showed that motor, cognitive, 317 
and brain imaging measures were well correlated and successfully identified a variant 318 
in MSH3 associated with composite progression7. Other studies show prediction 319 
accuracy of PD status or progression (such as development of cognitive impairment) 320 
is improved by combining multiple clinical, genetic, and biomarker factors6,22. 321 
In PD, there are many different scales for assessing symptoms. Each scale has a 322 
degree of measurement error4 and different sensitivity to progression of underlying 323 
symptoms23. PCA is a data-driven approach that combines multiple measures to 324 
identify latent components that explain the most variability in the data, and these may 325 
more accurately reflect disease progression. 326 
Our progression GWASs have identified two main findings. Firstly, we replicated 327 
previous findings for APOE ε4. Many studies have shown that the ε4 allele is 328 
associated with dementia in PD20,24–26, and potentially separately from the risk of 329 
Alzheimer’s disease (AD)27. One possible mechanism is that APOE is associated with 330 
amyloid- pathology, as comorbid AD pathology is common in PD patients with 331 
dementia (PDD) at postmortem28. Alternatively, APOE may drive cognitive decline 332 
independently of amyloid/AD pathology. Recent  animal model work has shown that 333 
the ε4 allele is independently associated with -synuclein pathology and toxicity29. In 334 
addition, the ε4 allele is overrepresented in Dementia with Lewy Body cases with ‘pure’ 335 
Lewy body pathology, compared to PDD cases30. A systematic review showed that 336 
limbic and neocortical -synuclein pathology had the strongest association with PD 337 
dementia28. Further work is needed to determine the mechanisms by which APOE 338 
influences cognitive decline. 339 
In the APOE locus, there may be multiple independent signals for cognitive 340 
progression. This is similar to AD, where there have been multiple risk loci located in 341 
Chromosome 19 in addition to APOE, including TOMM40, APOC1, and more distant 342 
genes. This study was not powered to conduct analyses stratified by APOE genotypes 343 
as has been done in AD31. Further work is needed to fine-map this region and 344 




We identified a novel signal in ATP8B2 associated with motor progression in a gene-346 
based analysis. This gene encodes an ATPase phospholipid transporter (type 8B, 347 
member 2). Phospholipid translocation may be important in the formation of transport 348 
vesicles32. This gene has not been reported in PD or other diseases, and needs to be 349 
tested in other cohorts. 350 
Our sensitivity analysis adjusting for LEDD suggests that levodopa may influence the 351 
absolute scores in the MDS-UPDRSIII but does not influence the rate of progression, 352 
and this has been shown in a previous study33. We also found that the mean rate of 353 
change in the MDS-UPDRSIII was comparable between Tracking Parkinson’s/Oxford 354 
Discovery and PPMI (Table 1), despite the different medication states. Together, these 355 
suggest that medication has not influenced our results for motor progression. 356 
We have shown that the genetics of PD risk and progression are largely separate. In 357 
our targeted analysis of PD risk variants, GBA p.E326K was nominally associated with 358 
composite and cognitive progression. Analysis of sequencing data showed that GBA 359 
status was strongly associated with composite and cognitive progression, but not 360 
motor progression. Previous studies show that GBA variants are associated with rapid  361 
progression and mortality34–39, however many of these studies have longer follow-up, 362 
or patients with longer disease duration. This may explain why we did not find a strong 363 
effect for motor progression, and is supported by analysis of GBA in patients earlier in 364 
disease stage15. In addition, previous studies have used different methods to measure 365 
progression.  Our unbiased genome-wide search suggests that, in addition to GBA, 366 
there are potentially other genes that are important for PD progression.  367 
Our targeted analysis showed that only a few PD risk variants were nominally 368 
associated with progression, similar to the previous PD progression GWAS18,40. This 369 
suggests that there is minimal overlap in the genetic architecture of PD risk and PD 370 
progression. Similarly, the age at onset GWAS showed only a partial overlap with the 371 
genetics of PD risk21. We now have the ability to study progression through the 372 
integration of detailed clinical data with genome-wide genetic variation in large-scale 373 
studies, and this can improve our understanding of the biology of progression. 374 
We did not replicate the finding for the SLC44A1 variant that was associated with 375 




have used different methods and a different phenotype to analyse PD progression. 377 
Further progression GWASs are needed to replicate both sets of results, and other 378 
metrics for PD progression could be analysed, such as mortality. 379 
While no other large genome-wide GWASs have investigated PD progression, many 380 
candidate gene studies have nominated common genetic factors associated with 381 
progression. Aside from APOE, common variants in MAPT1,41–43, COMT24,42, BDNF, 382 
MTHFR, and SORL144 have been reported to influence cognitive decline (reviewed in 383 
Fagan & Pihlstrom45) . For motor progression, other than GBA, common variants in 384 
SNCA have been suggested to influence the rate of decline, although these studies 385 
are small and have not been confirmed in large studies26,46–49. A small GWAS of motor 386 
and cognitive progression identified suggestive loci in C8orf4 and CLRN350, although 387 
these have not been replicated. A novel machine learning approach found that 388 
variation in LINGO2 was associated with change in the MDS-UPDRS51, although 389 
again this finding needs independent replication. We did not replicate these findings, 390 
possibly because we are underpowered as a GWAS to detect variants with smaller 391 
effects, or because we have analysed progression using different methods. However, 392 
many of these candidate gene studies are small and some associations have not been 393 
convincingly replicated. 394 
Our study has some limitations. Follow-up was limited to 72-months, and longer follow-395 
up is needed to detect variants which may influence progression in later disease 396 
stages, such as GBA.  397 
We may also be underpowered to detect variants with smaller effects on progression. 398 
Although the HD GWAS identified significant signals in smaller samples7, analysis of 399 
PD progression is more complex due to slower progression, greater heterogeneity in 400 
genetic risk and rate of progression between patients, and greater dissociation 401 
between motor and cognitive progression. Our findings need to be tested in 402 
independent cohorts, and the lack of independent replication is another limitation of 403 
this study. 404 
A third limitation is that symptom progression may be influenced by non-SNP variants 405 
(such as rare variants or structural variants) and gene-gene interactions that would be 406 




A final limitation is the potential inclusion of patients that have non-PD conditions. We 408 
did not find that our results changed substantially when we excluded patients with 409 
diagnostic certainty <90%. However, certainty data was not available for PPMI, and 410 
abnormal dopamine transporter scans cannot differentiate between PD and other 411 
degenerative parkinsonian conditions52. Despite this, our sensitivity analysis suggest 412 
that our results are not being driven by non-PD conditions. Our GWASs also did not 413 
identify loci that are associated with PSP risk, including MAPT, MOBP53, or rs2242367 414 
near LRRK2 associated with PSP progression54. 415 
Many of our top variants had weaker signals when we excluded the fastest and slowest 416 
progressing patients. With our duration of follow-up, we should have excluded the 417 
majority of non-PD patients as diagnostic accuracy improves after 5 years of disease 418 
duration1,55 however it is possible that some have not been excluded. Analysis of 419 
pathologically-confirmed PD cases is needed to resolve this issue. Alternatively, this 420 
may indicate that genotypes have different effects in the most extreme progressors. 421 
This could be due to co-morbidities such as vascular burden56, or interactions between 422 
synuclein and co-pathologies (such as amyloid, and tau)57,58 in the rapid progressors 423 
which exacerbates clinical progression. 424 
This study is the first to use a PCA data reduction method to assess PD progression, 425 
based on a successful approach in HD. We robustly replicated the association 426 
between APOE 4 and cognitive progression, and have identified other genes which 427 
may be important. These advances are essential to understand the biology of disease 428 
progression and nominate therapeutic targets to stop or slow PD progression. 429 




Data Availability 431 
Anonymised data from Tracking Parkinson’s and Oxford Discovery are available to 432 
researchers on application. Please apply via the project coordinators (tracking-433 
parkinsons@glasgow.ac.uk and parkinsons.discovery@nhs.net respectively). The 434 
PPMI data is publicly available on application (https://www.ppmi-info.org/access-435 
data-specimens/download-data/).  436 
Code is available at https://github.com/huw-morris-lab/PD-PCA-progression-GWAS. 437 
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Figure legends 719 
Figure 1. Steps to create composite, motor, and cognitive progression scores. 720 
 721 
Figure 2. Manhattan plot for GWAS of composite progression. The red dashed line 722 
indicates the genome-wide significance threshold p-value 5 x 10-8. The top genes from 723 
the MAGMA gene-based analysis and p values are shown on the right. 724 
 725 
Figure 3. Manhattan plot for the GWAS of motor progression. Genome-wide 726 
significance is the standard p-value 5 x 10-8 (not indicated in the figure). The top genes 727 
from the MAGMA gene-based analysis and p values are shown on the right. 728 
 729 
Figure 4. Manhattan plot for the variant-based GWAS of cognitive progression. The 730 
red dashed line indicates the genome-wide significance threshold p-value 5 x 10-8. 731 
The top genes from the MAGMA gene-based analysis and p values are shown on 732 
the right. 733 
 734 
 735 
 736 
